clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-5-6-385-399clinmed-855Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESМножественная системная атрофияMultiple system atrophyhttps://orcid.org/0000-0003-0632-6653ЮсуповФ. А.YusupovF. A.

Юсупов Фуркат Абдулахатович — д-р мед. наук, профессор, зав. кафедрой неврологии, нерохрургии и психиатрии, медицинского факультета

Ош

Furkat A. Yusupov — Doctor of Medical Sciences, Professor, Head of the Department of Neurology, Neurosurgery and Psychiatry, Faculty of Medicine

Osh

https://orcid.org/0000-0003-4839-1306ЫдырысовИ. Т.YdyrysovI. T.

Ыдырысов Исматилла Токтосунович — д-р мед. наук, профессор, декан медицинского факультета

Ош

Ismatilla T. Ydyrysov — Doctor of Medical Sciences, Professor, Dean of the Medical Faculty

Osh

https://orcid.org/0000-0002-4179-9205ЮлдашевА. А.YuldashevA. A.

Юлдашев Акмал Акбарович — аспирант кафедры неврологии, нейрохирургии и психиатрии медицинского факультета

Ош

Akmal A. Yuldashev — postgraduate student of the Department of Neurology, Neurosurgery and Psychiatry of the Medical Faculty

Osh

akmal.yuldashev.2017@list.ruОшский государственный университетКыргызстанOsh State UniversityKyrgyzstan2024071120241025-6385399Copyright © Юсупов Ф.А., Ыдырысов И.Т., Юлдашев А.А., 20242024Юсупов Ф.А., Ыдырысов И.Т., Юлдашев А.А.Yusupov F.A., Ydyrysov I.T., Yuldashev A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/855

Множественная системная атрофия (МСА) — быстро прогрессирующее нейродегенеративное заболевание, характеризующееся наличием вегетативной дисфункции и двигательных нарушений. В большинстве случаев оно возникает у взрослых и проявляется следующими клиническими синдромами различной выраженности: паркинсонизм, мозжечковые нарушения, вегетативная недостаточность, урогенитальная дисфункция и кортикоспинальные нарушения. Трудности диагностики и лечения МСА во многом связаны с неполным пониманием патогенеза заболевания. В этом обзоре обобщаются современные литературные данные об этиологических (в т.ч. генетических) факторах риска, патогенезе, клинике, диагностике, дифференциальной диагностике и лечении множественной системной атрофии.

Multiple systemic atrophy (MSA) is a rapidly progressive neurodegenerative disease characterized by the presence of autonomic dysfunction and movement disorders. It occurs in adults in most cases and is manifested by various clinical syndromes with varying degrees of severity, such as parkinsonism, cerebellar dysfunction, autonomic insufficiency, and urogenital and corticospinal dysfunction. Difficulties in diagnosis and treatment are largely due to incomplete understanding of pathogenesis. This review summarizes current literature on etiological, including genetic, risk factors, pathogenesis, clinical presentation, diagnosis, differential diagnosis, and treatment options for MSA.

множественная системная атрофиянейродегенеративные заболеванияпаркинсонизммозжечковые расстройстваmultiple systemic atrophyneurodegenerative diseasesparkinsonismReferencesFanciulli A., Wenning G.K. Multiple-system atrophy. N. Engl. J. Med. 2015;372(3):249–63. DOI: 10.1056/NEJMra1311488Fanciulli A., Wenning G.K. Multiple-system atrophy. N. Engl. J. Med. 2015;372(3):249–63. DOI: 10.1056/NEJMra1311488Wenning G.K., Stankovic I., Vignatelli L., Fanciulli A., Calandra-Buonaura G., Seppi K., Palma J.A., Meissner W.G., Krismer F., Berg D., Cortelli P., Freeman R., Halliday G., Höglinger G., Lang A., Ling H., Litvan I., Low P., Miki Y., Panicker J., Pellecchia M.T., Quinn N., Sakakibara R., Stamelou M., Tolosa E., Tsuji S., Warner T., Poewe W., Kaufmann H. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov. Disord. 2022;37(6):1131–1148. DOI: 10.1002/mds.29005Wenning G.K., Stankovic I., Vignatelli L., Fanciulli A., Calandra-Buonaura G., Seppi K., Palma J.A., Meissner W.G., Krismer F., Berg D., Cortelli P., Freeman R., Halliday G., Höglinger G., Lang A., Ling H., Litvan I., Low P., Miki Y., Panicker J., Pellecchia M.T., Quinn N., Sakakibara R., Stamelou M., Tolosa E., Tsuji S., Warner T., Poewe W., Kaufmann H. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov. Disord. 2022;37(6):1131–1148. DOI: 10.1002/mds.29005Gilman S., Low P.A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C.J., Kaufmann H., Klockgether T., Lang A.E., Lantos P.L., Litvan I., Mathias C.J., Oliver E., Robertson D., Schatz I., Wenning G.K. Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 1999;163(1):94–8. DOI: 10.1016/s0022-510x(98)00304-9Gilman S., Low P.A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C.J., Kaufmann H., Klockgether T., Lang A.E., Lantos P.L., Litvan I., Mathias C.J., Oliver E., Robertson D., Schatz I., Wenning G.K. Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 1999;163(1):94–8. DOI: 10.1016/s0022-510x(98)00304-9Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., Wood N.W., Colosimo C., Dürr A., Fowler C.J., Kaufmann H., Klockgether T., Lees A., Poewe W., Quinn N., Revesz T., Robertson D., Sandroni P., Seppi K., Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–6. DOI: 10.1212/01.wnl.0000324625.00404.15Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., Wood N.W., Colosimo C., Dürr A., Fowler C.J., Kaufmann H., Klockgether T., Lees A., Poewe W., Quinn N., Revesz T., Robertson D., Sandroni P., Seppi K., Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–6. DOI: 10.1212/01.wnl.0000324625.00404.15Quinn N. Multiple system atrophy--the nature of the beast. J. Neurol. Neurosurg. Psychiatry. 1989;Suppl(Suppl):78–89. DOI: 10.1136/jnnp.52.suppl.78Quinn N. Multiple system atrophy--the nature of the beast. J. Neurol. Neurosurg. Psychiatry. 1989;Suppl(Suppl):78–89. DOI: 10.1136/jnnp.52.suppl.78Geser F., Wenning G.K., Seppi K., Stampfer-Kountchev M., Scherfler C., Sawires M., Frick C., Ndayisaba J.P., Ulmer H., Pellecchia M.T., Barone P., Kim H.T., Hooker J., Quinn N.P., Cardozo A., Tolosa E., Abele M., Klockgether T., Østergaard K., Dupont E., Schimke N., Eggert K.M., Oertel W., Djaldetti R., Poewe W. European МСА Study Group. Progression of multiple system atrophy (МСА): a prospective natural history study by the European МСА Study Group (EМСА SG). Mov. Disord. 2006;21(2):179–86. DOI: 10.1002/mds.20678Geser F., Wenning G.K., Seppi K., Stampfer-Kountchev M., Scherfler C., Sawires M., Frick C., Ndayisaba J.P., Ulmer H., Pellecchia M.T., Barone P., Kim H.T., Hooker J., Quinn N.P., Cardozo A., Tolosa E., Abele M., Klockgether T., Østergaard K., Dupont E., Schimke N., Eggert K.M., Oertel W., Djaldetti R., Poewe W. European МСА Study Group. Progression of multiple system atrophy (МСА): a prospective natural history study by the European МСА Study Group (EМСА SG). Mov. Disord. 2006;21(2):179–86. DOI: 10.1002/mds.20678Wenning G.K., Tison F., Ben Shlomo Y., Daniel S.E., Quinn N.P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 1997;12(2):133–47. DOI: 10.1002/mds.870120203Wenning G.K., Tison F., Ben Shlomo Y., Daniel S.E., Quinn N.P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 1997;12(2):133–47. DOI: 10.1002/mds.870120203Goh Y.Y., Saunders E., Pavey S., Rushton E., Quinn N., Houlden H., Chelban V. Multiple system atrophy. Pract. Neurol. 2023;23(3):208–221. DOI: 10.1136/pn-2020-002797Goh Y.Y., Saunders E., Pavey S., Rushton E., Quinn N., Houlden H., Chelban V. Multiple system atrophy. Pract. Neurol. 2023;23(3):208–221. DOI: 10.1136/pn-2020-002797Poewe W., Stankovic I., Halliday G., Meissner WG., Wenning GK., Pellecchia MT., Seppi K., Palma JA., Kaufmann H. Multiple system atrophy. Nat Rev Dis Primers. 2022 25;8(1):56. DOI: 10.1038/s41572-022-00382-6Poewe W., Stankovic I., Halliday G., Meissner WG., Wenning GK., Pellecchia MT., Seppi K., Palma JA., Kaufmann H. Multiple system atrophy. Nat Rev Dis Primers. 2022 25;8(1):56. DOI: 10.1038/s41572-022-00382-6Kao A.W., Racine C.A., Quitania L.C., Kramer J.H., Christine C.W., Miller B.L. Cognitive and neuropsychiatric profi le of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis. Assoc. Disord. 2009;23(4):365– 70. DOI: 10.1097/WAD.0b013e3181b5065dKao A.W., Racine C.A., Quitania L.C., Kramer J.H., Christine C.W., Miller B.L. Cognitive and neuropsychiatric profi le of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis. Assoc. Disord. 2009;23(4):365– 70. DOI: 10.1097/WAD.0b013e3181b5065dHöglinger G.U., Respondek G., Stamelou M., Kurz C., Josephs K.A., Lang A.E., Mollenhauer B., Müller U., Nilsson C., Whitwell J.L., Arzberger T., Englund E., Gelpi E., Giese A., Irwin D.J., Meissner W.G., Pantelyat A., Rajput A., van Swieten J.C., Troakes C., Antonini A., Bhatia K.P., Bordelon Y., Compta Y., Corvol J.C., Colosimo C., Dickson D.W., Dodel R., Ferguson L., Grossman M., Kassubek J., Krismer F., Levin J., Lorenzl S., Morris H.R., Nestor P., Oertel W.H., Poewe W., Rabinovici G., Rowe J.B., Schellenberg G.D., Seppi K., van Eimeren T., Wenning G.K., Boxer A.L., Golbe L.I., Litvan I; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 2017;32(6):853–864. DOI: 10.1002/mds.26987Höglinger G.U., Respondek G., Stamelou M., Kurz C., Josephs K.A., Lang A.E., Mollenhauer B., Müller U., Nilsson C., Whitwell J.L., Arzberger T., Englund E., Gelpi E., Giese A., Irwin D.J., Meissner W.G., Pantelyat A., Rajput A., van Swieten J.C., Troakes C., Antonini A., Bhatia K.P., Bordelon Y., Compta Y., Corvol J.C., Colosimo C., Dickson D.W., Dodel R., Ferguson L., Grossman M., Kassubek J., Krismer F., Levin J., Lorenzl S., Morris H.R., Nestor P., Oertel W.H., Poewe W., Rabinovici G., Rowe J.B., Schellenberg G.D., Seppi K., van Eimeren T., Wenning G.K., Boxer A.L., Golbe L.I., Litvan I; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 2017;32(6):853–864. DOI: 10.1002/mds.26987Alexander S.K., Rittman T., Xuereb J.H., Bak T.H., Hodges J.R., Rowe J.B. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J. Neurol. Neurosurg. Psychiatry. 2014;85(8):925–9. DOI: 10.1136/jnnp-2013-307035Alexander S.K., Rittman T., Xuereb J.H., Bak T.H., Hodges J.R., Rowe J.B. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J. Neurol. Neurosurg. Psychiatry. 2014;85(8):925–9. DOI: 10.1136/jnnp-2013-307035Rektor I., Bohnen N.I., Korczyn A.D., Gryb V., Kumar H., Kramberger M.G., de Leeuw FE., Pirtošek Z., Rektorová I., Schlesinger I., Slawek J., Valkovič P., Veselý B. An updated diagnostic approach to subtype definition of vascular parkinsonism — Recommendations from an expert working group. Parkinsonism Relat. Disord. 2018;49:9–16. DOI: 10.1016/j.parkreldis.2017.12.030Rektor I., Bohnen N.I., Korczyn A.D., Gryb V., Kumar H., Kramberger M.G., de Leeuw FE., Pirtošek Z., Rektorová I., Schlesinger I., Slawek J., Valkovič P., Veselý B. An updated diagnostic approach to subtype definition of vascular parkinsonism — Recommendations from an expert working group. Parkinsonism Relat. Disord. 2018;49:9–16. DOI: 10.1016/j.parkreldis.2017.12.030Manto M., Gandini J., Feil K., Strupp M. Cerebellar ataxias: an update. Curr. Opin. Neurol. 2020;33(1):150–160. DOI: 10.1097/WCO.0000000000000774Manto M., Gandini J., Feil K., Strupp M. Cerebellar ataxias: an update. Curr. Opin. Neurol. 2020;33(1):150–160. DOI: 10.1097/WCO.0000000000000774Cortese A., Tozza S., Yau W.Y., Rossi S., Beecroft S.J., Jaunmuktane Z., Dyer Z., Ravenscroft G., Lamont P.J., Mossman S., Chancellor A., Maisonobe T., Pereon Y., Cauquil C., Colnaghi S., Mallucci G., Curro R., Tomaselli P.J., Thomas-Black G., Sullivan R., Efthymiou S., Rossor A.M., Laurá M., Pipis M., Horga A., Polke J., Kaski D., Horvath R., Chinnery P.F., Marques W., Tassorelli C., Devigili G., Leonardis L., Wood N.W., Bronstein A., Giunti P., Züchner S., Stojkovic T., Laing N., Roxburgh R.H., Houlden H., Reilly M.M. Cerebellar ataxia, neuropathy, vestibular arefl exia syndrome due to RFC1 repeat expansion. Brain. 2020;143(2):480–490. DOI: 10.1093/brain/awz418Cortese A., Tozza S., Yau W.Y., Rossi S., Beecroft S.J., Jaunmuktane Z., Dyer Z., Ravenscroft G., Lamont P.J., Mossman S., Chancellor A., Maisonobe T., Pereon Y., Cauquil C., Colnaghi S., Mallucci G., Curro R., Tomaselli P.J., Thomas-Black G., Sullivan R., Efthymiou S., Rossor A.M., Laurá M., Pipis M., Horga A., Polke J., Kaski D., Horvath R., Chinnery P.F., Marques W., Tassorelli C., Devigili G., Leonardis L., Wood N.W., Bronstein A., Giunti P., Züchner S., Stojkovic T., Laing N., Roxburgh R.H., Houlden H., Reilly M.M. Cerebellar ataxia, neuropathy, vestibular arefl exia syndrome due to RFC1 repeat expansion. Brain. 2020;143(2):480–490. DOI: 10.1093/brain/awz418Bourinaris T., Houlden H. C9orf72 and its Relevance in Parkinsonism and Movement Disorders: A Comprehensive Review of the Literature. Mov. Disord. Clin. Pract. 2018;5(6):575–585. DOI: 10.1002/mdc3.12677Bourinaris T., Houlden H. C9orf72 and its Relevance in Parkinsonism and Movement Disorders: A Comprehensive Review of the Literature. Mov. Disord. Clin. Pract. 2018;5(6):575–585. DOI: 10.1002/mdc3.12677Song J., Zhang Y., Lang Y., Wang Y.H., Shao J., Cui L. Parkinsonism and dysautonomia with anti-CV2/CRMP5 associated paraneoplastic neurological syndromes mimicking multiple system atrophy: a case report. BMC Neurol. 2021;21(1):408. DOI: 10.1186/s12883-021-02448-6Song J., Zhang Y., Lang Y., Wang Y.H., Shao J., Cui L. Parkinsonism and dysautonomia with anti-CV2/CRMP5 associated paraneoplastic neurological syndromes mimicking multiple system atrophy: a case report. BMC Neurol. 2021;21(1):408. DOI: 10.1186/s12883-021-02448-6Ricigliano V.A.G., Fossati B., Saraceno L., Cavalli M., Bazzigaluppi E., Meola G. МСА Mimic? Rare Occurrence of Anti-Hu Autonomic Failure and Thymoma in a Patient with Parkinsonism: Case Report and Literature Review. Front. Neurosci. 2018;12:17. DOI: 10.3389/fnins.2018.00017Ricigliano V.A.G., Fossati B., Saraceno L., Cavalli M., Bazzigaluppi E., Meola G. МСА Mimic? Rare Occurrence of Anti-Hu Autonomic Failure and Thymoma in a Patient with Parkinsonism: Case Report and Literature Review. Front. Neurosci. 2018;12:17. DOI: 10.3389/fnins.2018.00017Eschlböck S., Kiss G., Krismer F., Fanciulli A., Kaindlstorfer C., Raccagni C., Seppi K., Kiechl S., Panicker J.N., Wenning G.K. Urodynamic evaluation in multiple system atrophy: a retrospective cohort study. Mov. Disord. Clin. Pract. 2021;8(7):1052–1060. DOI: 10.1002/mdc3.13307Eschlböck S., Kiss G., Krismer F., Fanciulli A., Kaindlstorfer C., Raccagni C., Seppi K., Kiechl S., Panicker J.N., Wenning G.K. Urodynamic evaluation in multiple system atrophy: a retrospective cohort study. Mov. Disord. Clin. Pract. 2021;8(7):1052–1060. DOI: 10.1002/mdc3.13307Stankovic I., Fanciulli A., Kostic V.S., Krismer F., Meissner W.G., Palma J.A., Panicker J.N., Seppi K., Wenning G.K; MoDiМСА Study Group. Laboratory-supported multiple system atrophy beyond autonomic function testing and imaging: a systematic review by the MoDiМСА Study Group. Mov. Disord. Clin. Pract. 2021;8(3):322–340. DOI: 10.1002/mdc3.13158Stankovic I., Fanciulli A., Kostic V.S., Krismer F., Meissner W.G., Palma J.A., Panicker J.N., Seppi K., Wenning G.K; MoDiМСА Study Group. Laboratory-supported multiple system atrophy beyond autonomic function testing and imaging: a systematic review by the MoDiМСА Study Group. Mov. Disord. Clin. Pract. 2021;8(3):322–340. DOI: 10.1002/mdc3.13158Chelban V., Bocchetta M., Hassanein S., Haridy N.A., Houlden H., Rohrer J.D. An update on advances in magnetic resonance imaging of multiple system atrophy. J. Neurol. 2019;266(4):1036–1045. DOI: 10.1007/s00415-018-9121-3Chelban V., Bocchetta M., Hassanein S., Haridy N.A., Houlden H., Rohrer J.D. An update on advances in magnetic resonance imaging of multiple system atrophy. J. Neurol. 2019;266(4):1036–1045. DOI: 10.1007/s00415-018-9121-3Gilman S. Functional imaging with positron emission tomography in multiple system atrophy. J. Neural. Transm (Vienna). 2005;112(12):1647–55. DOI: 10.1007/s00702-005-0351-zGilman S. Functional imaging with positron emission tomography in multiple system atrophy. J. Neural. Transm (Vienna). 2005;112(12):1647–55. DOI: 10.1007/s00702-005-0351-zGilman S., Koeppe R.A., Junck L., Little R., Kluin K.J., Heumann M., Martorello S., Johanns J. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann. Neurol. 1999;45(6):769–77. DOI: 10.1002/1531-8249(199906)45:6<769::aid-ana11>3.0.co;2-gGilman S., Koeppe R.A., Junck L., Little R., Kluin K.J., Heumann M., Martorello S., Johanns J. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann. Neurol. 1999;45(6):769–77. DOI: 10.1002/1531-8249(199906)45:6<769::aid-ana11>3.0.co;2-gNicoletti G., Lodi R., Condino F., Tonon C., Fera F., Malucelli E., Manners D., Zappia M., Morgante L., Barone P., Barbiroli B., Quattrone A. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of МСА from Parkinson’s disease and progressive supranuclear palsy. Brain. 2006;129(Pt 10):2679–87. DOI: 10.1093/brain/awl166Nicoletti G., Lodi R., Condino F., Tonon C., Fera F., Malucelli E., Manners D., Zappia M., Morgante L., Barone P., Barbiroli B., Quattrone A. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of МСА from Parkinson’s disease and progressive supranuclear palsy. Brain. 2006;129(Pt 10):2679–87. DOI: 10.1093/brain/awl166Bega D., Kuo P.H., Chalkidou A., Grzeda M.T., Macmillan T., Brand C., Sheikh Z.H., Antonini A. Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. NPJ Parkinsons Dis. 2021;7(1):43. DOI: 10.1038/s41531-021-00185-8Bega D., Kuo P.H., Chalkidou A., Grzeda M.T., Macmillan T., Brand C., Sheikh Z.H., Antonini A. Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. NPJ Parkinsons Dis. 2021;7(1):43. DOI: 10.1038/s41531-021-00185-8Zhao P., Zhang B., Gao S., Li X. Clinical features, MRI, and 18F-FDG-PET in differential diagnosis of Parkinson disease from multiple system atrophy. Brain Behav. 2020;10(11):e01827. DOI: 10.1002/brb3.1827Zhao P., Zhang B., Gao S., Li X. Clinical features, MRI, and 18F-FDG-PET in differential diagnosis of Parkinson disease from multiple system atrophy. Brain Behav. 2020;10(11):e01827. DOI: 10.1002/brb3.1827Nagayama H., Ueda M., Yamazaki M., Nishiyama Y., Hamamoto M., Katayama Y. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov. Disord. 2010;25(11):1744–7. DOI: 10.1002/mds.23338Nagayama H., Ueda M., Yamazaki M., Nishiyama Y., Hamamoto M., Katayama Y. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov. Disord. 2010;25(11):1744–7. DOI: 10.1002/mds.23338Aerts M.B., Esselink R.A., Abdo W.F., Bloem B.R., Verbeek M.M. CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging. 2012;33(2):430.e1–3. DOI: 10.1016/j.neurobiolaging.2010.12.001Aerts M.B., Esselink R.A., Abdo W.F., Bloem B.R., Verbeek M.M. CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging. 2012;33(2):430.e1–3. DOI: 10.1016/j.neurobiolaging.2010.12.001Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fl uid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011;69(3):570–80. DOI: 10.1002/ana.22311Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fl uid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011;69(3):570–80. DOI: 10.1002/ana.22311Hall S., Öhrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., Nilsson C., Håkan W., Decraemer H., Någga K., Minthon L., Londos E., Vanmechelen E., Holmberg B., Zetterberg H., Blennow K., Hansson O. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 2012;69(11):1445–52. DOI: 10.1001/archneurol.2012.1654Hall S., Öhrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., Nilsson C., Håkan W., Decraemer H., Någga K., Minthon L., Londos E., Vanmechelen E., Holmberg B., Zetterberg H., Blennow K., Hansson O. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 2012;69(11):1445–52. DOI: 10.1001/archneurol.2012.1654Magdalinou N.K., Paterson R.W., Schott J.M., Fox N.C., Mummery C., Blennow K., Bhatia K., Morris H.R., Giunti P., Warner T.T., de Silva R., Lees A.J., Zetterberg H. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry. 2015;86(11):1240–7. DOI: 10.1136/jnnp-2014-309562Magdalinou N.K., Paterson R.W., Schott J.M., Fox N.C., Mummery C., Blennow K., Bhatia K., Morris H.R., Giunti P., Warner T.T., de Silva R., Lees A.J., Zetterberg H. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry. 2015;86(11):1240–7. DOI: 10.1136/jnnp-2014-309562Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Döring F., Trenkwalder C., Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fl uid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10(3):230–40. DOI: 10.1016/S1474-4422(11)70014-XMollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Döring F., Trenkwalder C., Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fl uid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10(3):230–40. DOI: 10.1016/S1474-4422(11)70014-XMollenhauer B., Bibl M., Esselmann H., Steinacker P., Trenkwalder C., Wiltfang J., Otto M. Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J. Neural. Transm (Vienna). 2007;114(7):919–27. DOI: 10.1007/s00702-007-0629-4Mollenhauer B., Bibl M., Esselmann H., Steinacker P., Trenkwalder C., Wiltfang J., Otto M. Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J. Neural. Transm (Vienna). 2007;114(7):919–27. DOI: 10.1007/s00702-007-0629-4Bech S., Hjermind L.E., Salvesen L., Nielsen J.E., Heegaard N.H., Jørgensen H.L., Rosengren L., Blennow K., Zetterberg H., Winge K. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat. Disord. 2012;18(1):69–72. DOI: 10.1016/j.parkreldis.2011.08.012Bech S., Hjermind L.E., Salvesen L., Nielsen J.E., Heegaard N.H., Jørgensen H.L., Rosengren L., Blennow K., Zetterberg H., Winge K. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat. Disord. 2012;18(1):69–72. DOI: 10.1016/j.parkreldis.2011.08.012Palma J.A., Norcliffe-Kaufmann L., Kaufmann H. Diagnosis of multiple system atrophy. Auton Neurosci. 2018;211:15–25. DOI: 10.1016/j.autneu.2017.10.007Palma J.A., Norcliffe-Kaufmann L., Kaufmann H. Diagnosis of multiple system atrophy. Auton Neurosci. 2018;211:15–25. DOI: 10.1016/j.autneu.2017.10.007Wenning G.K., Ben Shlomo Y., Magalhães M., Daniel S.E., Quinn N.P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994;117(4):835–45. DOI: 10.1093/brain/117.4.835Wenning G.K., Ben Shlomo Y., Magalhães M., Daniel S.E., Quinn N.P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994;117(4):835–45. DOI: 10.1093/brain/117.4.835Eschlböck S., Wenning G., Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J. Neural. Transm (Vienna). 2017;124(12):1567–1605. DOI: 10.1007/s00702-017-1791-yEschlböck S., Wenning G., Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J. Neural. Transm (Vienna). 2017;124(12):1567–1605. DOI: 10.1007/s00702-017-1791-yMantovani G., Marozzi I., Rafanelli M., Rivasi G., Volpato S., Ungar A. Supine hypertension: A state of the art. Auton. Neurosci. 2022;241:102988. DOI: 10.1016/j.autneu.2022.102988Mantovani G., Marozzi I., Rafanelli M., Rivasi G., Volpato S., Ungar A. Supine hypertension: A state of the art. Auton. Neurosci. 2022;241:102988. DOI: 10.1016/j.autneu.2022.102988Jane Hall S., Harrison S., Harding C., Reid S., Parkinson R. British Association of Urological Surgeons suprapubic catheter practice guidelines — revised. BJU Int. 2020;126(4):416–422. DOI: 10.1111/bju.15123Jane Hall S., Harrison S., Harding C., Reid S., Parkinson R. British Association of Urological Surgeons suprapubic catheter practice guidelines — revised. BJU Int. 2020;126(4):416–422. DOI: 10.1111/bju.15123South A.R., Somers S.M., Jog M.S. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology. 2010;74(15):1198–202. DOI: 10.1212/WNL.0b013e3181d9002bSouth A.R., Somers S.M., Jog M.S. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology. 2010;74(15):1198–202. DOI: 10.1212/WNL.0b013e3181d9002bCortelli P., Calandra-Buonaura G., Benarroch EE., Giannini G., Iranzo A., Low P.A. et al. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology. 2019;93(14):630–639. DOI: 10.1212/WNL.0000000000008208Cortelli P., Calandra-Buonaura G., Benarroch EE., Giannini G., Iranzo A., Low P.A. et al. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology. 2019;93(14):630–639. DOI: 10.1212/WNL.0000000000008208Gilat M., Marshall NS., Testelmans D., Buyse B., Lewis S.J.G. A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: time for more and larger randomized placebo-controlled trials. J. Neurol. 2022;269(1):125–148. DOI: 10.1007/s00415-020-10353-0Gilat M., Marshall NS., Testelmans D., Buyse B., Lewis S.J.G. A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: time for more and larger randomized placebo-controlled trials. J. Neurol. 2022;269(1):125–148. DOI: 10.1007/s00415-020-10353-0Iranzo A. Sleep and breathing in multiple system atrophy. Curr. Treat. Options Neurol. 2007;9(5):347–53. PMID: 17716598.Iranzo A. Sleep and breathing in multiple system atrophy. Curr. Treat. Options Neurol. 2007;9(5):347–53. PMID: 17716598.

The authors declare that there are no conflicts of interest present.